Ronald Blue Trust, Inc. Nektar Therapeutics Transaction History

Ronald Blue Trust, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 18, 2024	BUY	$0.42 - $0.57 $152 - $206	362 New	362 $0
Q1 2023 Apr 17, 2023	SELL	$0.64 - $3.15 $16 - $81	-26 Reduced 28.57%	65 $0
Q4 2022 Jan 17, 2023	SELL	$2.03 - $4.28 $371 - $783	-183 Reduced 66.79%	91 $0
Q3 2022 Oct 21, 2022	BUY	$3.04 - $5.14 $756 - $1,279	249 Added 996.0%	274 $1,000
Q2 2022 Aug 09, 2022	BUY	$3.17 - $6.17 $79 - $154	25 New	25 $0

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

Stay updated on Ronald Blue Trust, Inc. with notifications on news.